Rubedo reports early results for RLS-1496 targeting skin

Rubedo Life Sciences has positive news about its initial human study on RLS-1496, an anti-aging compound

ContentsEarly trial results show encouraging outcomesNext steps for RLS-1496Advancements in longevity researchThe four-week European trial proved to be safe and showed an initial indication of effectiveness in reversing aging on the skin

The biotech firm said that the results were better than they expected in a Phase 1 trial.

The new proposed drug is called RLS-1496, and it aims to help in attacking the old or zombie cells that are bringing about skin aging and other aging-related diseases

The trial was aimed at testing the safety and tolerability of the drug and seeking some preliminary information on the effects of the drug in human subjects.

Early trial results show encouraging outcomes

Phase 1 clinical trials involved patients with skin allergies like eczema, psoriasis, and sun-damaged skin

Rubedo stated that the treatment was also tolerated, and there were no serious side effects. Due to medications given in mid- and high-dose dosages, the number of aged cells decreased in patients.

Among the eczematous participants, a significant reduction in skin itching was seen in 25% of the participants. Individuals with psoriasis experienced a mean of 20% decrease in the skin thickness

In subjects with sun-damaged skin, RLS-1496 seemed to elevate collagen gene and protein expression, which promotes skin firmness

Frederick Beddingfield, the CEO of Rubedo, emphasized that observing clinical effects in a Phase 1 dermatology trial is not typical, considering the brief duration of the study and a small sample size.

Next steps for RLS-1496

Later in the year, Rubedo will carry out a second study in the United States. The new trial will look into the ability of RLS-1496 to treat precancerous skin spots, which are actinic keratosis

Altogether, the two trials will involve some 70 human subjects. It is projected that the company will realize a greater amount of information by the year 2026, which may help determine whether or not the drug can reverse and not just slow skin aging.

Advancements in longevity research

Anti-aging research is a field that is improving with biotech companies transitioning from the theoretical to clinical trials. A few start-ups are also making significant advancements in coming up with therapies that will target the aging process

The LEV Foundation, led by Aubrey de Grey, is also partnering with Human Longevity, Inc. to apply AI in research on age differences in humans. They study the old population (the oldest of the old) to guide them in drug development to slow down the aging process.

Coinbase CEO Brian Armstrong is also a co-founder of biotech NewLimit, which has created a prototype drug that rejuvenates elderly human hepatocytes

The company is experimenting with epigenetic reprogramming so that it can enhance the functions of cells with age. These advances indicate the increasing trend in the longevity industry and imply the possible breakthrough within the next few years.

The clinical trial of Rubedo (RLS-1496) has shown a good move in the direction of clinically approved anti-aging treatments. Due to the expansion of research, the findings might leave a mark on the future of the field of dermatology and the treatment of age-related diseases.